Milan Scheidegger has a multidisciplinary background in medicine (MD), neuroscience (PhD), philosophy (MA), psychiatry and psychotherapy. He is driven by the passion to understand the nature of consciousness from its molecular basis up to the level of phenomenal experience.
As a senior physician he is currently leading the Psychedelic Research & Therapy Development group at the Department of Psychiatry, Psychotherapy, and Psychosomatics at the University Hospital of Psychiatry Zurich. After his MD-PhD training in functional and molecular brain imaging at the Institute for Biomedical Engineering (ETH Zurich) he continues to research the neurobiology and pharmacology of altered states of consciousness and the therapeutic potential of psychedelics such as ketamine, psilocybin, ayahuasca and DMT.
He co-founded Reconnect Labs, an academic spin-off at the University of Zurich, and Reconnect Foundation, a non-profit organization based in Switzerland, with the mission to develop transformative treatments for mental health care. As a psychotherapist he is trained in interpersonal and cognitive behavioral therapy, ego-state therapy, acceptance and commitment therapy, mindfulness-based and psychedelic-assisted therapy.
Beyond empirical research, he earned an MA degree in History and Philosophy of Knowledge (ETH Zurich) with focus on philosophy of mind, neurophenomenology, mindfulness and deep ecology. On his ethnobotanical expeditions to Mexico, Colombia and Brazil, he explored the traditional use of psychoactive plants in indigenous rituals.
He is engaged in the public discourse and education around psychedelic therapy and has given talks to both academic and non-academic audiences. His contributions to the field of psychedelic therapy were acknowledged by the Young Investigators Award from the Swiss Society of Biological Psychiatry (2013) and the Inger-Salling Price for Psychiatry (2019).